THE OPPORTUNITY
Why Now
Several forces are converging to create an exceptional market window:
Type 2 diabetes and metabolic syndrome are at all-time highs globally
driving urgent demand for sweetener alternatives
Erythritol has faced fresh cardiovascular concerns, creating instability in the sugar alcohol category
The sports nutrition and functional beverage sectors are actively seeking sweetener innovations that support rather than compromise health positioning
Stevia’s bitterness and inconsistency have long frustrated formulators the category is searching for the next step
The clean-label movement has made artificial sweeteners increasingly untenable for mainstream brands
GLYVIA™ has already attracted significant acquisition interest from major buyers.
We are pursuing our own commercialization strategy first but the validation is clear.
THE TECHNOLOGY MOAT
Why GLYVIA™ is Defensible
Commodity ingredients are vulnerable. Patented technologies are not.
GLYVIA is protected by a patent covering the specific amino acid–glycoside complexing technology
Clinical blood glucose data, Health Canada and FDA approval status, and an approved health claim create a regulatory moat that commodity sweeteners cannot cross
The formulation was developed by a credentialed Ph.D. pharmacologist with two decades of nutraceutical research
The technology has already been validated commercially through NU SWEET by NUNU Bioceuticals; real consumer sales, real repeat purchase, real market proof
REVENUE MODELS
Multiple Paths to Revenue
The GLYVIA™ technology platform supports several parallel revenue streams:
Bulk ingredient licensing to brands and manufacturers (recurring)
White label co-manufacturing contracts (project + recurring)
Standalone GLYVIA™ consumer brand (retail, DTC)
Technology licensing and royalty agreements
Strategic acquisition or brand partnership at scale
BIOLOGIC PHARMAMEDICAL
The Company Behind GLYVIA™
Biologic Pharmamedical is a Canadian nutraceutical research and manufacturing company based in Vancouver, BC. Founded by Dr. Franco Cavaleri, the company has developed a portfolio of patented nutraceutical technologies spanning metabolic health, cardiovascular support, cognitive performance, and longevity.
GLYVIA™ represents the company’s most commercially scalable technology a platform ingredient that serves multiple industries simultaneously.